Terms: = Prostate cancer AND SYK, P43405, 6850, ENSG00000165025
15 results:
1. Meta-analysis of
Yu W; Zhao M; Deng Y; Liu S; Du G; Yan B; Zhao Z; Sun N; Guo J
Cancer Imaging; 2023 Aug; 23(1):77. PubMed ID: 37605288
[TBL] [Abstract] [Full Text] [Related]
2. [The comparison of modified ESUR score and Mehralivand grade based on biparametric MRI for assessing extracapsulare extension in prostate cancer].
Yang LQ; Jin PF; Bao J; Wang XM
Zhonghua Yi Xue Za Zhi; 2023 May; 103(19):1469-1476. PubMed ID: 37198109
[No Abstract] [Full Text] [Related]
3. Cartilage oligomeric matrix protein acts as a molecular biomarker in multiple cancer types.
Guo B; Wang Y; Liu W; Zhang S
Clin Transl Oncol; 2023 Feb; 25(2):535-554. PubMed ID: 36255654
[TBL] [Abstract] [Full Text] [Related]
4. Inherited TP53 Variants and Risk of prostate cancer.
Maxwell KN; Cheng HH; Powers J; Gulati R; Ledet EM; Morrison C; Le A; Hausler R; Stopfer J; Hyman S; Kohlmann W; Naumer A; Vagher J; Greenberg SE; Naylor L; Laurino M; Konnick EQ; Shirts BH; AlDubayan SH; Van Allen EM; Nguyen B; Vijai J; Abida W; Carlo MI; Dubard-Gault M; Lee DJ; Maese LD; Mandelker D; Montgomery B; Morris MJ; Nicolosi P; Nussbaum RL; Schwartz LE; Stadler Z; Garber JE; Offit K; Schiffman JD; Nelson PS; Sartor O; Walsh MF; Pritchard CC
Eur Urol; 2022 Mar; 81(3):243-250. PubMed ID: 34863587
[TBL] [Abstract] [Full Text] [Related]
5. Anti-prostate cancer activity of a nanoformulation of the spleen tyrosine kinase (syk) inhibitor C61.
Sahin TK; Aktepe OH; Uckun FM; Yalcin S
Anticancer Drugs; 2020 Jul; 31(6):609-616. PubMed ID: 32044796
[TBL] [Abstract] [Full Text] [Related]
6. Preoperative prostate health index predicts poor pathologic outcomes of radical prostatectomy in patients with biopsy-detected low-risk patients prostate cancer: results from a Chinese prospective cohort.
Tang B; Han CT; Lu XL; Wan FN; Zhang CZ; Zhu Y; Ye DW
Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):64-70. PubMed ID: 29213105
[TBL] [Abstract] [Full Text] [Related]
7. Longitudinal tracking of subpopulation dynamics and molecular changes during LNCaP cell castration and identification of inhibitors that could target the PSA-/lo castration-resistant cells.
Rycaj K; Cho EJ; Liu X; Chao HP; Liu B; Li Q; Devkota AK; Zhang D; Chen X; Moore J; Dalby KN; Tang DG
Oncotarget; 2016 Mar; 7(12):14220-40. PubMed ID: 26871947
[TBL] [Abstract] [Full Text] [Related]
8. syk is a candidate kinase target for the treatment of advanced prostate cancer.
Ghotra VP; He S; van der Horst G; Nijhoff S; de Bont H; Lekkerkerker A; Janssen R; Jenster G; van Leenders GJ; Hoogland AM; Verhoef EI; Baranski Z; Xiong J; van de Water B; van der Pluijm G; Snaar-Jagalska BE; Danen EH
Cancer Res; 2015 Jan; 75(1):230-40. PubMed ID: 25388286
[TBL] [Abstract] [Full Text] [Related]
9. A novel and essential role for FcγRIIa in cancer cell-induced platelet activation.
Mitrugno A; Williams D; Kerrigan SW; Moran N
Blood; 2014 Jan; 123(2):249-60. PubMed ID: 24258815
[TBL] [Abstract] [Full Text] [Related]
10. A genome-wide search for loci interacting with known prostate cancer risk-associated genetic variants.
Tao S; Wang Z; Feng J; Hsu FC; Jin G; Kim ST; Zhang Z; Gronberg H; Zheng LS; Isaacs WB; Xu J; Sun J
Carcinogenesis; 2012 Mar; 33(3):598-603. PubMed ID: 22219177
[TBL] [Abstract] [Full Text] [Related]
11. Biological activity of piceatannol: leaving the shadow of resveratrol.
Piotrowska H; Kucinska M; Murias M
Mutat Res; 2012; 750(1):60-82. PubMed ID: 22108298
[TBL] [Abstract] [Full Text] [Related]
12. The ERBB3 receptor in cancer and cancer gene therapy.
Sithanandam G; Anderson LM
Cancer Gene Ther; 2008 Jul; 15(7):413-48. PubMed ID: 18404164
[TBL] [Abstract] [Full Text] [Related]
13. Survey of differentially methylated promoters in prostate cancer cell lines.
Wang Y; Yu Q; Cho AH; Rondeau G; Welsh J; Adamson E; Mercola D; McClelland M
Neoplasia; 2005 Aug; 7(8):748-60. PubMed ID: 16207477
[TBL] [Abstract] [Full Text] [Related]
14. [Gene expression profiles of protein kinases and phosphatases obtained by hybridization with cDNA arrays: molecular portrait of human prostate carcinoma].
Kniazev IuP; Cheburkin IuV; Spikermann K; Peter S; Jenster G; Bangma KH; Karelin MI; Shkol'nik MI; Urbanskiĭ AI; Evtushenko VI; Ullrich A; Kniazev PG
Mol Biol (Mosk); 2003; 37(1):97-111. PubMed ID: 12624952
[TBL] [Abstract] [Full Text] [Related]
15. Comparison of prostate-specific antigen (PSA) measured by four combinations of free PSA and total PSA assays.
Junker R; Brandt B; Zechel C; Assmann G
Clin Chem; 1997 Sep; 43(9):1588-94. PubMed ID: 9299938
[TBL] [Abstract] [Full Text] [Related]
